APA (7th ed.) Citation

Bennett, M. G. A., Meakin, A. S., Botting-Lawford, K. J., Niu, Y., Ford, S. G., Murphy, M. P., . . . Morrison, J. L. (2025). Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone. Pharmaceutics, 17(3), 285. https://doi.org/10.3390/pharmaceutics17030285

Chicago Style (17th ed.) Citation

Bennett, Millicent G. A., Ashley S. Meakin, Kimberley J. Botting-Lawford, Youguo Niu, Sage G. Ford, Michael P. Murphy, Michael D. Wiese, Dino A. Giussani, and Janna L. Morrison. "Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone." Pharmaceutics 17, no. 3 (2025): 285. https://doi.org/10.3390/pharmaceutics17030285.

MLA (9th ed.) Citation

Bennett, Millicent G. A., et al. "Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone." Pharmaceutics, vol. 17, no. 3, 2025, p. 285, https://doi.org/10.3390/pharmaceutics17030285.